WO2001058494A3 - Matieres et procedes destines au traitement de troubles oculaires - Google Patents

Matieres et procedes destines au traitement de troubles oculaires Download PDF

Info

Publication number
WO2001058494A3
WO2001058494A3 PCT/US2001/004203 US0104203W WO0158494A3 WO 2001058494 A3 WO2001058494 A3 WO 2001058494A3 US 0104203 W US0104203 W US 0104203W WO 0158494 A3 WO0158494 A3 WO 0158494A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid sequence
sequence encoding
ocular
gene therapy
Prior art date
Application number
PCT/US2001/004203
Other languages
English (en)
Other versions
WO2001058494A2 (fr
Inventor
Imre Kovesdi
Douglas E Brough
Duncan L Mcvey
Lisa Wei
Original Assignee
Genvec Inc
Imre Kovesdi
Douglas E Brough
Duncan L Mcvey
Lisa Wei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/599,997 external-priority patent/US6821775B1/en
Application filed by Genvec Inc, Imre Kovesdi, Douglas E Brough, Duncan L Mcvey, Lisa Wei filed Critical Genvec Inc
Priority to JP2001557602A priority Critical patent/JP2003522160A/ja
Priority to EP01909022A priority patent/EP1253948A2/fr
Priority to CA002398571A priority patent/CA2398571A1/fr
Priority to AU36818/01A priority patent/AU780634C/en
Publication of WO2001058494A2 publication Critical patent/WO2001058494A2/fr
Publication of WO2001058494A3 publication Critical patent/WO2001058494A3/fr
Priority to US10/211,701 priority patent/US20030045498A1/en
Priority to AU2005202935A priority patent/AU2005202935A1/en
Priority to US11/610,364 priority patent/US20070098692A1/en
Priority to US12/237,036 priority patent/US20090018100A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé destiné au traitement prophylactique ou thérapeutique d'un animal pour au moins un trouble oculaire, comme par exemple, une néovascularisation oculaire ou une dégénérescence maculaire liée à l'âge. Ce procédé consiste à mettre une cellule oculaire en contact avec un vecteur d'expression comprenant une séquence d'acide nucléique codant un inhibiteur de l'angiogénèse et la même séquence d'acide nucléique ou une séquence différente codant un agent neurotrophique. Ce procédé consiste également à mettre une cellule oculaire en contact avec différents vecteurs d'expression, chacun comprenant une séquence d'acide nucléique codant un inhibiteur de l'angiogénèse et/ou une séquence d'acide nucléique codant un agent neurotrophique. De plus, la présente invention concerne un vecteur viral comprenant une séquence d'acide nucléique codant le pigment epithelium-derived factor (PEDF) ou un fragment thérapeutique de celui-ci.
PCT/US2001/004203 2000-02-11 2001-02-09 Matieres et procedes destines au traitement de troubles oculaires WO2001058494A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2001557602A JP2003522160A (ja) 2000-02-11 2001-02-09 眼関連疾患の治療のための遺伝子治療
EP01909022A EP1253948A2 (fr) 2000-02-11 2001-02-09 Matieres et procedes destines au traitement de troubles oculaires
CA002398571A CA2398571A1 (fr) 2000-02-11 2001-02-09 Matieres et procedes destines au traitement de troubles oculaires
AU36818/01A AU780634C (en) 2000-02-11 2001-02-09 Gene Therapy for treating ocular-related disorders
US10/211,701 US20030045498A1 (en) 2000-02-11 2002-08-02 Materials and methods for treating ocular-related disorders
AU2005202935A AU2005202935A1 (en) 2000-02-11 2005-07-06 Gene therapy for treating ocular-related disorders
US11/610,364 US20070098692A1 (en) 2000-02-11 2006-12-13 Materials and methods for treating ocular-related disorders
US12/237,036 US20090018100A1 (en) 2000-02-11 2008-09-24 Materials and methods for treating ocular-related disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18174300P 2000-02-11 2000-02-11
US60/181,743 2000-02-11
US09/599,997 2000-06-23
US09/599,997 US6821775B1 (en) 2000-02-11 2000-06-23 Viral vector encoding pigment epithelium-derived factor
US22833700P 2000-08-28 2000-08-28
US60/228,337 2000-08-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/599,997 Continuation-In-Part US6821775B1 (en) 2000-02-11 2000-06-23 Viral vector encoding pigment epithelium-derived factor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/211,701 Continuation US20030045498A1 (en) 2000-02-11 2002-08-02 Materials and methods for treating ocular-related disorders

Publications (2)

Publication Number Publication Date
WO2001058494A2 WO2001058494A2 (fr) 2001-08-16
WO2001058494A3 true WO2001058494A3 (fr) 2002-04-04

Family

ID=27391455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004203 WO2001058494A2 (fr) 2000-02-11 2001-02-09 Matieres et procedes destines au traitement de troubles oculaires

Country Status (5)

Country Link
EP (1) EP1253948A2 (fr)
JP (1) JP2003522160A (fr)
AU (1) AU780634C (fr)
CA (1) CA2398571A1 (fr)
WO (1) WO2001058494A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240946A1 (fr) 2018-06-11 2019-12-19 The Regents Of The University Of California Déméthylation pour traiter une maladie oculaire

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2006054278A2 (fr) 2004-11-16 2006-05-26 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Variants du facteur derive de l'epithelium pigmentaire et utilisations correspondantes
EP2266656B1 (fr) * 2005-04-18 2020-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Appareil pour l'administration de composés thérapeutiques dans la sphère oculaire d'un sujet.
JP2007291009A (ja) * 2006-04-25 2007-11-08 Seitai Shigen Laboratory Inc 血管内膜肥厚抑制剤
WO2009126894A2 (fr) * 2008-04-11 2009-10-15 Massachusetts Eye And Ear Infirmary Procédés et compositions pour le diagnostic et le traitement de troubles angiogènes
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014159546A1 (fr) * 2013-03-14 2014-10-02 Asklepios Biopharmaceutical, Inc. Gènes de recepteur-1 vegf soluble modifié et vecteurs pour une thérapie génique
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
US20210207166A1 (en) * 2018-01-23 2021-07-08 Southern Eye Equipment Expression vector and method
AU2019288296B2 (en) * 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CN112672732A (zh) * 2018-06-19 2021-04-16 细胞疗法有限责任公司 包含神经营养剂、凋亡信号传导片段抑制剂（FAS）或FAS配体（FASL）抑制剂、肿瘤坏死因子-α（TNF-α）或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶的药物递送系统
AU2020407072A1 (en) * 2019-12-18 2022-07-07 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461749A (en) * 1994-05-31 1995-10-31 Minnesota Mining And Manufacturing Company Floor mop and cleaning system
WO1995033480A1 (fr) * 1994-06-07 1995-12-14 The Government Of The United States Of America, Re Facteur derive de l'epithelium pigmentaire: caracterisation, organisation genomique et sequence de son gene
US5840686A (en) * 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
WO1999026480A1 (fr) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Vecteurs de therapie genique anti-angiogenique et leurs applications dans le cadre du traitement d'affections liees a l'angiogenese
WO2000054813A2 (fr) * 1999-03-15 2000-09-21 Chiron Corporation Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
WO1999004806A1 (fr) * 1997-07-23 1999-02-04 Northwestern University Procedes et compositions pour inhiber l'angiogenese
EP1015620B1 (fr) * 1997-09-23 2005-08-31 Genvec, Inc. Cassette d edouble selection et compositions les contenant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840686A (en) * 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US5461749A (en) * 1994-05-31 1995-10-31 Minnesota Mining And Manufacturing Company Floor mop and cleaning system
WO1995033480A1 (fr) * 1994-06-07 1995-12-14 The Government Of The United States Of America, Re Facteur derive de l'epithelium pigmentaire: caracterisation, organisation genomique et sequence de son gene
WO1999026480A1 (fr) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Vecteurs de therapie genique anti-angiogenique et leurs applications dans le cadre du traitement d'affections liees a l'angiogenese
WO2000054813A2 (fr) * 1999-03-15 2000-09-21 Chiron Corporation Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. W. DAWSON ET AL: "Pigment Epithelium-Derive Factor: A Potent Inhibitor of Angiogenesis", SCIENCE, vol. 285, 9 July 1999 (1999-07-09), pages 245 - 248, XP002135983 *
See also references of EP1253948A2 *
STEELE F R ET AL: "PIGMENT EPITHELIUM-DERIVED FACTOR: NEUROTROPHIC ACTIVITY AND IDENTIFICATION AS A MEMBER OF THE SERINE PROTEASE INHIBITOR GENE FAMILY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, 1 February 1993 (1993-02-01), pages 1526 - 1530, XP000606398, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240946A1 (fr) 2018-06-11 2019-12-19 The Regents Of The University Of California Déméthylation pour traiter une maladie oculaire

Also Published As

Publication number Publication date
CA2398571A1 (fr) 2001-08-16
WO2001058494A2 (fr) 2001-08-16
EP1253948A2 (fr) 2002-11-06
AU780634B2 (en) 2005-04-07
JP2003522160A (ja) 2003-07-22
AU3681801A (en) 2001-08-20
AU780634C (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2001058494A3 (fr) Matieres et procedes destines au traitement de troubles oculaires
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
MX2020010994A (es) Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
WO1997013866A3 (fr) Vecteurs de recombinaison du virus herpetique pour une expression des cellules neuronales
EP1276756A1 (fr) Proteines de fusion d'albumine
WO2002002624A3 (fr) Molecules de type b7 et utilisation de ces molecules
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
WO2002024891A3 (fr) Molecules semblables a b7 (b7-like, b7-l) et utilisations correspondantes
WO2003060071A3 (fr) Proteines hybrides d'albumine
WO2006050211A3 (fr) Therapie genique a base de proteine decarboxylase d'acide glutamique a administration peripherique pour lutter contre la douleur engendree par un traumatisme medullaire
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
WO2002024234A3 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
BR9508019B1 (pt) Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica.
WO2001072957A3 (fr) Molecules de type facteur de croissance des fibroblastes et leurs utilisations
WO2001092308A3 (fr) Polypeptides a noeud de cystines: molecules 'cloaked-2' et leurs utilisations
PT1080202E (pt) Distribuicao de vectores aav codificando aadc intensificada por conveccao
WO2001061007A3 (fr) Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
WO2004050027A3 (fr) Procedes et materiaux destines a traiter des troubles oculaires
WO2001042474A3 (fr) Molecules de type interferon et utilisations
EP1149917A3 (fr) Vecteurs derivés du virus Hépatitis B pour la thérapie gènique
WO2002010388A3 (fr) Molecules du type recepteur de complement c3b/c4b et utilisations de ces molecules
WO2001003728A3 (fr) Therapie genique destinee au renforcement et/ou a l'induction de l'angiogenese
WO1999012576A3 (fr) Procedes et compositions utiles pour traiter des troubles cardiaques et renaux au moyen d'une therapie genique de peptide natriuretique auriculaire et de kallikreine de tissu
EP0763205A4 (fr) Sequences d'acides nucleiques regulant l'expression de genes specifiques aux poumons
WO2002101076A3 (fr) Procedes d'expression ciblee d'un acide nucleique therapeutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2398571

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 36818/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10211701

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 557602

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001909022

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001909022

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 36818/01

Country of ref document: AU